Fig. 1 · Structure

Documents & Downloads

Diclofenamide

Cat. No. A10303 CAS 120-97-8

Carbonic anhydrase inhibitor

Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Diclofenamide (dichlorphenamide) bound purified human carbonic anhydrases I and II in native mass-spectrometry assays, with Kd values of 1.3 ± 0.1 μM and 0.027 ± 0.002 μM, respectively. These binding constants describe target affinity and are distinct from catalytic inhibition endpoints. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Carbonic anhydrase

Diclofenamide Research Summary

This section summarizes 3 in vitro studies of Diclofenamide from 2 published references. In vitro models include HEK293T cells transiently expressing wild-type human ClC-1.

Diclofenamide In Vitro Studies

At 100 μM, diclofenamide increased human ClC-1 chloride currents in transfected HEK293T cells. In isolated rat muscle, 50–100 μM increased resting chloride conductance without a significant potassium-conductance change. The cellular activation shift depended on the recording protocol; a causal acidification mechanism and in vivo efficacy were not established by these experiments. [2]

Binding to human carbonic anhydrases I and II

Biochemical assay · Purified human carbonic anhydrases I and II from human erythrocytes; native nano-ESI mass spectrometry. [1]

Individual-ligand measurements showed stronger binding to hCA II than hCA I. Six-ligand competition measurements gave similar Kd values. These are dissociation constants, not inhibition potencies; the competition experiment is assay validation rather than a therapeutic combination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to hCA I in individual-ligand assayKd 1.3 ± 0.1 μM[1]
Binding to hCA II in individual-ligand assayKd 0.027 ± 0.002 μM[1]
Six-ligand competition binding assayKd hCA I: 1.4 ± 0.1 μM; hCA II: 0.035 ± 0.002 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
hCA I individual assay: 1, 2, 3 and 4 μM DCP with 5 μM protein (SI Table S1). Competition assay: 4 μM DCP with 20 μM hCA I or II; other ligands 4 μM each except indapamide 15 μM.
Exposure duration
Protein–ligand mixtures equilibrated for at least 30 min at room temperature.
Method
Native nano-electrospray ionization MS using ~250 nm inner-diameter emitter tips.
Vehicle
Aqueous 70 mM ammonium acetate, pH 7.4.
Co-treatment
Competition check used ethoxzolamide, brinzolamide, furosemide, indapamide and acetazolamide alongside dichlorophenamide.
Reported limits
The reviewed SI Table S1 describes hCA I concentrations; hCA II individual-assay concentrations are not specified in the reviewed locations and are not borrowed from hCA I. Table 2 and SI Table S2 do not specify SD versus SEM.
Methods and source locations

Compound reported in the paper: Diclofenamide (dichlorophenamide); Compound label in the paper: dichlorophenamide; L4 in Figure 5

Applies to the named compound in the reported assay; no Adooq lot or formulation validation.

Table 2 and footnotes; Figures 1/5 and captions; Experimental Section; SI Scheme S1 and Table S1

Binding to hCA I in individual-ligand assay: ~250 nm emitters; average of triplicate measurements at different ligand concentrations. Table 2 does not define the ± statistic. — Table 2, dichlorophenamide row, hCA I single column; footnote a

Binding to hCA II in individual-ligand assay: Same measurement design; uncertainty retained as tabulated. — Table 2, dichlorophenamide row, hCA II single column; footnote a

Six-ligand competition binding assay: Triplicate measurements of a single mixture; ± statistic not defined in Table 2. — Table 2, dichlorophenamide row, competition columns; footnote b; Figure 5

Recombinant human ClC-1 chloride currents

Cell-based study · HEK293T cells transiently expressing wild-type human ClC-1. [2]

DCP increased steady-state inward chloride current at −80 mV, slowed deactivation and shifted channel activation toward more negative voltages. A longer pulse protocol confirmed a smaller but significant activation shift. These cellular responses do not establish direct binding to ClC-1 or prove intracellular acidification as the causal route.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Steady-state chloride current change at −80 mV, 400 ms test protocolRelative change 81 ± 30%; n=8 cells; P<0.006[2]
Negative shift of activation voltage dependence, 400 ms protocolVoltage shift −38.1 ± 8.9 mV; n=8 cells; P<0.004[2]
Activation shift with prolonged test pulses to address incomplete deactivationNegative shift magnitude 20.8 ± 3.9 mV; n=9 cells; P<0.001[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
Steady state after 2–4 min.
Method
Whole-cell patch clamp at 20–22°C; within-cell drug-free baseline comparison.
Vehicle
DMSO not above 0.2% v/v in recording solutions (Methods 2.5).
Reported limits
Methods 2.5 says pipette pH 7.4, whereas Results 3.1 says 7.2; exact pipette pH is unresolved. Vehicle-only response is not separately quantified in the reviewed locations.
Methods and source locations

Compound reported in the paper: Diclofenamide (dichlorphenamide); Compound label in the paper: DCP

Compound-level relevance to diclofenamide; supplier material, not an Adooq lot.

Methods 2.1/2.5; Results 3.1, pp.9–10; Table 1 p.24; Figure 1 and caption p.26

Steady-state chloride current change at −80 mV, 400 ms test protocol: Paired Student t test against the same cells before drug; mean ± SEM. — Results 3.1, printed p.9; Figure 1A–D; Table 1 and caption

Negative shift of activation voltage dependence, 400 ms protocol: Paired Student t test; mean ± SEM. — Results 3.1, printed p.9; Figure 1D; Table 1

Activation shift with prolonged test pulses to address incomplete deactivation: 800 ms test pulses; paired Student t test; mean ± SEM. — Results 3.1, printed p.10; Table 1, DCP 800 ms rows

Resting chloride conductance in isolated rat muscle

Cell-based study · Isolated extensor digitorum longus muscle fibers from adult male Wistar rats (3 months old); ex vivo bath exposure. [2]

DCP increased resting sarcolemmal chloride conductance at both tested concentrations, without a significant effect on potassium conductance. No significant difference between 50 and 100 μM was reported. This was isolated-muscle exposure, not an in vivo efficacy test.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Resting chloride conductance versus drug-free controlDirection/significance Increased at 50 and 100 μM; both marked *P<0.01 versus respective control.[2]
Resting potassium conductance and concentration comparisonLimiting result No significant gK effect; no significant difference between 50 and 100 μM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 or 100 μM
Exposure duration
20 min
Method
Bath incubation of isolated rat EDL muscle; current-clamp conductance measurement.
Vehicle
DMSO not above 0.2% v/v in physiological solution (Methods 2.5).
Reported limits
Per-animal replication for individual Figure 2 groups is not specified in the caption. Fiber counts are displayed in the figure; these are not independent animal counts. No systemic DCP dose applies.
Methods and source locations

Compound reported in the paper: Diclofenamide (dichlorphenamide); Compound label in the paper: DCP

Compound-level relevance to diclofenamide; supplier material, not an Adooq lot.

Methods 2.2/2.3/2.5; Results 3.2; Figure 2 and caption

Resting chloride conductance versus drug-free control: Two intracellular microelectrodes, current clamp, 30°C. gCl calculated as total resting conductance minus potassium conductance; Figure 2 bars mean ± SEM of fibers. — Results 3.2, printed pp.10–11; Figure 2 DCP middle panels; caption p.26

Resting potassium conductance and concentration comparison: Unpaired Student t test versus respective control for plotted conductances; no exact bar-height values inferred. — Results 3.2, printed p.11; Figure 2 DCP panels and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 120-97-8
Applications Carbonic anhydrase inhibitor
Formula C6H6Cl2N2O4S2
Molecular Weight 305.16
Synonyms Diclophenamide
SMILES
C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (183.51 mM)
Water Insoluble
Ethanol 30 mg/mL (98.3 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Diclofenamide Research References

  1. [1] Giang T. H. Nguyen, Thinh N. Tran, Matthew N. Podgorski, et al. Nanoscale Ion Emitters in Native Mass Spectrometry for Measuring Ligand–Protein Binding Affinities ACS Central Science (2019). PMID: 30834319 DOI: 10.1021/acscentsci.8b00787 Source material
  2. [2] Concetta Altamura, Adriano Fonzino, Nancy Tarantino, et al. Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders Experimental Neurology (2021). PMID: 33991525 DOI: 10.1016/j.expneurol.2021.113758 Source material

Added to your cart

View Cart Checkout
Loading...